Sanofi ships U.S. influenza vaccines for the 2024/25 season
Sanofi has begun shipping influenza vaccines across the U.S. for the 2024/25 flu season, starting on July 10, with shipments continuing through October. These vaccines, including Fluzone High-Dose, Flublok, and Fluzone, are designed to protect against three strains of influenza identified as the most likely to cause illness this season. Sanofi emphasizes the importance of flu vaccination to reduce risks such as pneumonia and cardiac events, especially in vulnerable populations. The company, a leader in global vaccine distribution, aims to support fall immunization campaigns by supplying healthcare providers, pharmacies, and other immunizers.
- Sanofi has started shipping its influenza vaccines for the 2024/25 season, ensuring early availability.
- Sanofi's vaccines are trivalent, offering protection against the three most likely influenza strains.
- The company distributes over 500 million vaccines annually, underscoring its significant market presence.
- Shipments of vaccines will continue through October, suggesting potential delays in full availability for the flu season.
Sanofi's early shipment of influenza vaccines signals a proactive approach to the upcoming flu season. This early distribution can ensure that healthcare providers and pharmacies are well-stocked, which is important for meeting demand. Ensuring vaccine availability ahead of the peak flu season minimizes risks of shortages, which can directly impact public health outcomes.
From an investor's perspective, Sanofi's strong supply chain and early shipment reflect operational efficiency. This move may lead to higher revenue generation in the short term due to increased sales volume. Additionally, being a leading provider of vaccines, Sanofi maintains a competitive edge by ensuring that their products are readily available when needed.
It's important to note that the selection of trivalent vaccines based on collaborative reviews by the FDA, WHO and CDC underlines Sanofi's commitment to aligning with global health standards. This adherence not only bolsters their reputation but also assures investors of the reliability and efficacy of their vaccines.
Sanofi's high-dose influenza vaccines, such as Fluzone High-Dose, have been proven to offer better protection against serious complications of flu in older adults. This is particularly important because the elderly are at a higher risk of severe outcomes from influenza, including pneumonia and cardiac events. This enhanced protective capability can lead to a reduction in healthcare costs associated with flu-related hospitalizations and treatments.
Furthermore, the company's diverse vaccine portfolio, covering all age groups, showcases its commitment to comprehensive public health solutions. However, investors should be aware of the potential side effects and contraindications associated with these vaccines. Transparency in disclosing this information is key for maintaining public trust and helps prevent legal and reputational risks.
In the long term, continued research and development in vaccine efficacy and safety can strengthen Sanofi's market position and lead to sustainable growth. By focusing on areas with higher unmet medical needs, Sanofi can also pave the way for future innovations in vaccine technology.
- Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns.
- Sanofi annual higher-dose influenza (flu) vaccinations have been proven to help protect from flu and shown to better protect from serious complications of flu such as pneumonia and cardiac events when compared to standard dose vaccines in older adults.
Thomas Grenier
Head of Vaccines,
"Today, we began shipping flu vaccines for the upcoming season, a moment that underscores our long-standing commitment to providing global protection against disease. Getting a flu shot is imperative to not only help protect against flu infection, but also to help reduce the risks of its potentially severe complications, which can lead to hospitalizations, especially in those most vulnerable. Sanofi understands what these populations need out of their flu shots and works tirelessly from start to finish to provide proven and specific solutions."
All flu vaccines provided by Sanofi to the US market are trivalent, meaning they offer protection against the current three strains of influenza (two influenza A strains and one influenza B strain). These strains were selected based on a collaborative review of influenza surveillance by the
Annual flu vaccination is one of the best ways to help protect against flu and its complications. Public health authorities worldwide reiterate their recommendations for eligible people to be vaccinated every year.
As one of the largest providers of influenza vaccines to
Indication and Important Safety Information for Fluzone® High-Dose (Influenza Vaccine), Flublok® (Influenza Vaccine) and Fluzone ® (Influenza Vaccine)
What are Fluzone® (Influenza Vaccine), Flublok® (Influenza Vaccine), and Fluzone® High-Dose (Influenza Vaccine)?
Fluzone, Flublok, and Fluzone High-Dose are vaccines indicated for the prevention of disease caused by influenza A and B strains contained in the vaccine. Fluzone is given to people 6 months of age and older. Flublok is given to people 18 years of age and older. Fluzone High-Dose is given to people 65 years of age and older.
IMPORTANT SAFETY INFORMATION FOR FLUZONE® (INFLUENZA VACCINE), FLUBLOK® (INFLUENZA VACCINE), AND FLUZONE® HIGH-DOSE (INFLUENZA VACCINE)
Fluzone, Flublok, or Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for Fluzone and Fluzone High-Dose). In addition, Fluzone and Fluzone High-Dose should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.
Tell your health care provider if you have ever had Guillain-Barré syndrome (severe muscle weakness) after a previous influenza vaccination.
If Fluzone, Flublok, or Fluzone High-Dose are given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected.
Vaccination with Fluzone, Flublok, or Fluzone High-Dose may not protect all people who receive the vaccine.
Fainting has occurred following vaccination with Fluzone, Flublok, and Fluzone High-Dose. Procedures should be in place to avoid injury from fainting.
For Fluzone, in children 6 months through 8 years of age, the most common side effects were pain or tenderness and redness where you got the shot, irritability, drowsiness (6 month through 35 months), and muscle pain (3 years through 8 years). In adults 18 years through 64 years of age, the most common side effects were pain where you got the shot, headache, and muscle pain. In adults over 65 years of age, the most common side effects were pain where you got the shot, headache, muscle pain, and general discomfort.
For Flublok, in adults 18 through 64 years of age, the most common side effects were pain where you got the shot, headache, tiredness, and muscle pain. In adults 65 years of age and older, the most common side effects were pain where you got the shot, tiredness and headache.
For Fluzone High-Dose, in adults 65 years of age and older, the most common side effects were pain where you got the shot, muscle pain, tiredness, and headache.
For Fluzone, Flublok, and Fluzone High-Dose, other side effects may occur.
For more information, talk to your healthcare professional and refer to the full Prescribing and Patient information for Flublok, Fluzone or Fluzone High-Dose.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Contacts
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com
Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Sanofi Forward-Looking Statements
This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
MAT-US-2406730-v1.0-07/2024
View original content:https://www.prnewswire.com/news-releases/sanofi-ships-us-influenza-vaccines-for-the-202425-season-302194084.html
SOURCE Sanofi
FAQ
When did Sanofi start shipping influenza vaccines for the 2024/25 season?
Which influenza vaccines are included in Sanofi's 2024/25 portfolio?
What strains do Sanofi's influenza vaccines protect against?
Why is flu vaccination important according to Sanofi?
How long will Sanofi's vaccine shipments continue?
